Zimmer Partners LP raised its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 488,300 shares of the company's stock after purchasing an additional 85,800 shares during the quarter. Zimmer Partners LP's holdings in Sanofi were worth $23,551,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Arkadios Wealth Advisors grew its position in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after acquiring an additional 751 shares in the last quarter. Kentucky Trust Co acquired a new position in shares of Sanofi in the 4th quarter worth approximately $436,000. Van ECK Associates Corp grew its position in shares of Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock worth $31,965,000 after acquiring an additional 101,726 shares in the last quarter. Sound Income Strategies LLC grew its position in shares of Sanofi by 156,520.9% in the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company's stock worth $3,248,000 after acquiring an additional 67,304 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Sanofi by 128.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company's stock worth $5,558,000 after acquiring an additional 64,747 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Stock Performance
SNY stock traded down $0.53 during trading on Friday, reaching $51.98. 1,833,730 shares of the company's stock were exchanged, compared to its average volume of 2,378,504. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company's fifty day moving average price is $52.78 and its 200-day moving average price is $51.89. The firm has a market cap of $131.32 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.55.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the previous year, the firm posted $1.78 EPS. The firm's quarterly revenue was down 11.0% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.
Sanofi Increases Dividend
The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is 57.14%.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $63.33.
Get Our Latest Stock Report on Sanofi
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
